Last $3.36 USD
Change Today -0.02 / -0.59%
Volume 191.3K
OGXI On Other Exchanges
Symbol
Exchange
Munich
NASDAQ CM
As of 12:04 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

OncoGenex Pharmaceuticals, Inc. announced that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the first interim futility analysis. The Phase 3 ENSPIRIT trial is an international, randomized, open-label trial designed to evaluate a survival benefit for custirsen in the treatment of advanced or metastatic non-small cell lung cancer in 1,100 patients who have progressed after initial chemotherapy treatment. Patients are randomized to receive custirsen plus docetaxel or docetaxel alone. Patient enrollment to ENSPIRIT was initiated by Teva in September 2012. Two interim futility analyses are planned for stopping the trial. The first of these two futility analyses has now been completed which allows for acceleration of further enrollment. A second futility analysis will be conducted later in the trial. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the evaluation of custirsen in the ENSPIRIT trial.

OncoGenex Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

OncoGenex Pharmaceuticals, Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported collaboration revenue of $4.929 million against $6.340 million a year ago. Loss from operations was $7.630 million against $9.396 million a year ago. Net loss was $7.015 million or $0.47 per basic and diluted share against $8.420 million or $0.57 per basic and diluted share a year ago. For the six months, the company reported collaboration revenue of $16.660 million against $11.416 million a year ago. Loss from operations was $15.559 million against $17.675 million a year ago. Net loss was $15.651 million or $1.05 per basic and diluted share against $15.117 million or $1.03 per basic and diluted share a year ago.

OncoGenex Pharmaceuticals, Inc. Appoints John A. Bencich as Vice President and Chief Financial Officer, Effective August 11, 2014

OncoGenex Pharmaceuticals, Inc. announced the appointment of John A. Bencich as Vice President and Chief Financial Officer (CFO). John Bencich is joining the company effective August 11, 2014. John will lead the company's financial and administrative operations, reporting directly to OncoGenex President and CEO Scott Cormack. Prior to his recent appointment at OncoGenex, John served as CFO of Integrated Diagnostics Inc. Before joining Integrated Diagnostics in 2012, John was CFO of Allozyne. Earlier he served as the vice president, CFO and treasurer of Trubion Pharmaceuticals.

OncoGenex Pharmaceuticals, Inc. to Report Q2, 2014 Results on Aug 07, 2014

OncoGenex Pharmaceuticals, Inc. announced that they will report Q2, 2014 results at 10:00 AM, GMT Standard Time on Aug 07, 2014

OncoGenex Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 07, 2014

OncoGenex Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $3.36 USD -0.02

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies
 

Industry Analysis

OGXI

Industry Average

Valuation OGXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.